Autopsy report · NCT00964704

A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“No patients have been recruited therefore study has been cancelled”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Hoffmann-La Roche
Sponsor type: Industry
Conditions: Breast Cancer
Interventions: bevacizumab [Avastin]; capecitabine [Xeloda]; docetaxel; trastuzumab [Herceptin]
Participants: 0

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.